N/A Completed N=22 Treatment

The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers

Postoperative Pain

Source: ClinicalTrials.gov NCT00657358 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2014

Primary outcomePrimary: Ischemic Pain — 4.31; 3.49; 3.44 units on a scale — p=<0.001

Summary

The purpose of this study is to study if lidocaine, given intravenously, reduces pain.

Outcome Measures

Outcome	Result	p-value
PRIMARY Ischemic Pain	4.31; 3.49; 3.44	<0.001 sig
PRIMARY Electrical Pain	2.40; 2.04; 2.52	—
PRIMARY Heat Pain	3.01; 2.83; 2.82	—
PRIMARY Cold Pain	42; 50.6; 51.2	—
PRIMARY Tactile Sensation	.28; .27; .27	—

Eligibility Criteria

Inclusion Criteria

Healthy Adult Volunteers, age >19 years

Exclusion Criteria

History of Substance Abuse
Coronary Artery Disease (CAD): unstable
Congestive Heart Failure (CHF): unstable
Heart Arrhythmia: symptomatic
Chronic Obstructive Pulmonary Disease (COPD)
Lidocaine Allergy
Diagnostic and Statistical Manual of Mental Disorders (Rev IV): Axis I: Common Axis I disorders include depression, anxiety disorders,bipolar disorder, ADHD, and schizophrenia. Axis II: borderline personality disorder, schizotypal personality disorder, antisocial personality disorder, and mild mental retardation.
Presence of Contraindications for MRI
Presence of electronically, magnetically, and mechanically activated implants
Electronically, magnetically, and mechanically activated implants
Ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators
Cardiac pacemakers
Metallic splinters in the eye
Ferromagnetic haemostatic clips in the central nervous system (CNS)
Claustrophobia
Pregnancy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00657358). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.